Galmed Pharmaceuticals (GLMD) Competitors $2.22 +0.04 (+1.60%) As of 09:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLMD vs. LPTX, IMCC, SNPX, BTAI, NERV, PHIO, BGXX, EQ, ABP, and BCLIShould you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Leap Therapeutics (LPTX), IM Cannabis (IMCC), Synaptogenix (SNPX), BioXcel Therapeutics (BTAI), Minerva Neurosciences (NERV), Phio Pharmaceuticals (PHIO), Bright Green (BGXX), Equillium (EQ), Abpro (ABP), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "pharmaceutical products" industry. Galmed Pharmaceuticals vs. Its Competitors Leap Therapeutics IM Cannabis Synaptogenix BioXcel Therapeutics Minerva Neurosciences Phio Pharmaceuticals Bright Green Equillium Abpro Brainstorm Cell Therapeutics Galmed Pharmaceuticals (NASDAQ:GLMD) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation. Is GLMD or LPTX more profitable? Galmed Pharmaceuticals' return on equity of -32.21% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Galmed PharmaceuticalsN/A -32.21% -28.59% Leap Therapeutics N/A -162.15%-120.05% Does the media refer more to GLMD or LPTX? In the previous week, Galmed Pharmaceuticals and Galmed Pharmaceuticals both had 1 articles in the media. Galmed Pharmaceuticals' average media sentiment score of 1.89 beat Leap Therapeutics' score of 1.87 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Galmed Pharmaceuticals Very Positive Leap Therapeutics Very Positive Do institutionals & insiders hold more shares of GLMD or LPTX? 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Comparatively, 7.5% of Leap Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, GLMD or LPTX? Galmed Pharmaceuticals has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.28, meaning that its share price is 128% less volatile than the S&P 500. Do analysts rate GLMD or LPTX? Leap Therapeutics has a consensus price target of $3.38, suggesting a potential upside of 867.05%. Given Leap Therapeutics' higher possible upside, analysts plainly believe Leap Therapeutics is more favorable than Galmed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger valuation & earnings, GLMD or LPTX? Leap Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalmed PharmaceuticalsN/AN/A-$7.52M-$16.66-0.13Leap TherapeuticsN/AN/A-$67.56M-$1.70-0.21 SummaryGalmed Pharmaceuticals beats Leap Therapeutics on 8 of the 10 factors compared between the two stocks. Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLMD vs. The Competition Export to ExcelMetricGalmed PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.59M$2.41B$5.51B$9.31BDividend YieldN/A1.79%4.25%4.09%P/E Ratio-0.139.1828.1819.72Price / SalesN/A762.22439.19110.06Price / CashN/A160.6835.5357.53Price / Book0.234.698.235.67Net Income-$7.52M$30.99M$3.23B$257.51M7 Day Performance9.61%-0.20%-0.61%-0.16%1 Month Performance32.84%8.67%6.63%9.89%1 Year Performance-41.88%-4.17%27.07%15.08% Galmed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLMDGalmed Pharmaceuticals1.4024 of 5 stars$2.23+1.6%N/A-39.6%$3.59MN/A-0.1320Positive NewsGap DownLPTXLeap Therapeutics2.2352 of 5 stars$0.28-2.6%$3.38+1,089.2%-84.4%$12.07MN/A-0.1740Positive NewsIMCCIM Cannabis0.1618 of 5 stars$3.30+11.5%N/A+28.6%$11.97M$39.44M-5.16340Gap UpSNPXSynaptogenix0.3118 of 5 stars$8.50+5.2%$14.00+64.7%+118.4%$11.82MN/A-0.844Positive NewsBTAIBioXcel Therapeutics4.2269 of 5 stars$1.90-1.6%$42.60+2,142.1%-90.9%$11.69M$2.27M-0.1490Positive NewsNERVMinerva Neurosciences4.2318 of 5 stars$1.64-0.6%$5.00+204.9%-37.2%$11.54MN/A2.009Gap DownPHIOPhio Pharmaceuticals2.5729 of 5 stars$2.55+6.3%$14.00+449.0%-48.4%$11.52MN/A-0.4010News CoverageBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002News CoverageGap DownEQEquillium2.6906 of 5 stars$0.32-0.6%$3.00+840.4%-54.4%$11.47M$41.10M-0.8240News CoverageABPAbproN/A$0.19-0.6%$4.00+2,040.2%N/A$11.43M$180K0.0015Positive NewsBCLIBrainstorm Cell Therapeutics1.296 of 5 stars$1.14-1.7%$30.00+2,531.6%-80.2%$11.41MN/A-0.3440News Coverage Related Companies and Tools Related Companies LPTX Competitors IMCC Competitors SNPX Competitors BTAI Competitors NERV Competitors PHIO Competitors BGXX Competitors EQ Competitors ABP Competitors BCLI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLMD) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
